172 related articles for article (PubMed ID: 38395838)
21. Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters.
Katsui K; Ogata T; Watanabe K; Katayama N; Kuroda M; Kiura K; Hiraki T; Maeda Y; Toyooka S; Kanazawa S
Cancer Med; 2020 Jul; 9(13):4540-4549. PubMed ID: 32364685
[TBL] [Abstract][Full Text] [Related]
22. Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
Bi N; Liang J; Zhou Z; Chen D; Fu Z; Yang X; Feng Q; Hui Z; Xiao Z; Lv J; Wang X; Zhang T; Wang X; Deng L; Wang W; Wang J; Liu L; Hu C; Wang L
JAMA Netw Open; 2019 Dec; 2(12):e1918070. PubMed ID: 31851351
[TBL] [Abstract][Full Text] [Related]
23. Effect of Interstitial Lung Abnormality on Concurrent Chemoradiotherapy-treated Stage III Non-small Cell Lung Cancer Patients.
Jeong WG; Kim YH; Ahn SJ; Jeong JU; Lee BC; Cho IJ; Kim YH
Anticancer Res; 2023 Apr; 43(4):1797-1807. PubMed ID: 36974810
[TBL] [Abstract][Full Text] [Related]
24. The incidence of and risk factors for radiation pneumonitis in patients treated with simultaneous bevacizumab and thoracic radiotherapy.
Chen F; Niu J; Wang M; Zhu H; Guo Z
Radiat Oncol; 2024 May; 19(1):67. PubMed ID: 38816745
[TBL] [Abstract][Full Text] [Related]
25. Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation.
Yegya-Raman N; Friedes C; Lee SH; Iocolano M; Duan L; Wang X; Li B; Aggarwal C; Cohen RB; Su W; Doucette A; Levin WP; Cengel KA; DiBardino D; Teo BK; O'Reilly SE; Sun L; Bradley JD; Xiao Y; Langer CJ; Feigenberg SJ
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1445-1454. PubMed ID: 37619788
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study.
Yin Y; Zhou Z; Li Z; Shen M; Qin Y; Yang C; Wang R; Kang M
Radiat Oncol; 2022 Jul; 17(1):135. PubMed ID: 35906636
[TBL] [Abstract][Full Text] [Related]
27. Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer.
Tsujino K; Hashimoto T; Shimada T; Yoden E; Fujii O; Ota Y; Satouchi M; Negoro S; Adachi S; Soejima T
J Thorac Oncol; 2014 Jul; 9(7):983-990. PubMed ID: 24922010
[TBL] [Abstract][Full Text] [Related]
28. Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung Cancer.
Torre-Bouscoulet L; Muñoz-Montaño WR; Martínez-Briseño D; Lozano-Ruiz FJ; Fernández-Plata R; Beck-Magaña JA; García-Sancho C; Guzmán-Barragán A; Vergara E; Blake-Cerda M; Gochicoa-Rangel L; Maldonado F; Arroyo-Hernández M; Arrieta O
Respir Res; 2018 Apr; 19(1):72. PubMed ID: 29690880
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer.
Bao Y; Peng F; Zhou QC; Yu ZH; Li JC; Cheng ZB; Chen L; Hu X; Chen YY; Wang J; Wang Y; Ma HL; Xu ZM; Lu RB; Deng XW; Chen M
Radiother Oncol; 2015 Feb; 114(2):161-6. PubMed ID: 25497558
[TBL] [Abstract][Full Text] [Related]
30. Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone.
Abe T; Saito S; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
Thorac Cancer; 2021 Jan; 12(2):245-250. PubMed ID: 33289347
[TBL] [Abstract][Full Text] [Related]
31. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
Wang Y; Deng L; Wang J; Zhang T; Wang W; Wang X; Liu W; Wu Y; Lv J; Feng Q; Zhou Z; Wang J; Wang L; Wang Z; Bi N
Front Immunol; 2023; 14():1341584. PubMed ID: 38288117
[TBL] [Abstract][Full Text] [Related]
32. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer.
Altan M; Soto F; Xu T; Wilson N; Franco-Vega MC; Simbaqueba Clavijo CA; Shannon VR; Faiz SA; Gandhi S; Lin SH; Lopez P; Zhong L; Akhmedzhanov F; Godoy MCB; Shroff GS; Wu J; Khawaja F; Kim ST; Naing A; Heymach JV; Daniel-Macdougall C; Liao Z; Sheshadri A
Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):630-639. PubMed ID: 37507279
[TBL] [Abstract][Full Text] [Related]
33. Risk factors of radiation pneumonitis in patients with NSCLC treated with concomitant chemoradiotherapy--Are we underestimating diabetes?--Turkish oncology group (TOG)/Lung cancer study group.
Ergen SA; Dincbas FO; Yücel B; Altınok P; Akyurek S; Korkmaz Kıraklı E; Ulger S; Etiz D; Yilmaz U; Kılıc D; Bozcuk H
Clin Respir J; 2020 Sep; 14(9):871-879. PubMed ID: 32470205
[TBL] [Abstract][Full Text] [Related]
34. Neutrophil-lymphocyte ratio and a dosimetric factor for predicting symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
Lee YH; Choi HS; Jeong H; Kang KM; Song JH; Lee WS; Lee GW; Song HN; Kim HG; Kang MH; Rhee DY; Jeong BK
Clin Respir J; 2018 Mar; 12(3):1264-1273. PubMed ID: 28618180
[TBL] [Abstract][Full Text] [Related]
35. Endostar, an Antiangiogenesis Inhibitor, Combined With Chemoradiotherapy for Locally Advanced Cervical Cancer.
Lu H; Wu Y; Liu X; Huang H; Jiang H; Zhu C; Man Y; Chen Z; Long X; Pang Q; Peng L; Li X; Gu J; Deng S; Xing L
Oncol Res; 2022 Jan; 28(9):929-944. PubMed ID: 34544526
[TBL] [Abstract][Full Text] [Related]
36. Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study.
Sugimoto T; Fujimoto D; Sato Y; Tamiya M; Yokoi T; Tamiya A; Iwasawa S; Hata A; Uchida J; Fukuda Y; Hara S; Kanazu M; Hirano K; Kokubo M; Yamamoto N
Invest New Drugs; 2021 Jun; 39(3):853-859. PubMed ID: 33405089
[TBL] [Abstract][Full Text] [Related]
37. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
Barriger RB; Fakiris AJ; Hanna N; Yu M; Mantravadi P; McGarry RC
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1381-6. PubMed ID: 20231061
[TBL] [Abstract][Full Text] [Related]
38. Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study.
Tsukita Y; Yamamoto T; Mayahara H; Hata A; Takeda Y; Nakayama H; Tanaka S; Uchida J; Usui K; Toyoda T; Tamiya M; Morimoto M; Oya Y; Kodaira T; Miyauchi E; Jingu K; Sugiura H
Radiother Oncol; 2021 Jul; 160():266-272. PubMed ID: 34023330
[TBL] [Abstract][Full Text] [Related]
39. [Outcome of concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer patients].
Liu L; Wang X; Ji Z; Wang J; Bi N; Hui Z; Lyu J; Liang J; Zhou Z; Feng Q; Chen D; Zhang H; Xiao Z; Yin W; Wang L
Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):863-7. PubMed ID: 26887520
[TBL] [Abstract][Full Text] [Related]
40. Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer.
Sakagami M; Inokuchi H; Mukumoto N; Itoyama H; Hamaura N; Yamagishi M; Mukumoto N; Matsuda S; Kabata D; Shibuya K
Radiat Oncol; 2023 May; 18(1):87. PubMed ID: 37217919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
